Список литературы

1. Hehlmann R. et al. Chronic myeloid leukaemia//The Lancet. - 2007. - Т. 370. - N. 9584. - С. 342 - 350.

2. Куликов С.М. и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009 - 2012 гг//Терапевтический архив (архив до 2018 г.). - 2014. - Т. 86. - N. 7. - С. 24 - 30.

3. Туркина А.Г. и др. Регистр больных хроническим миелолейкозом в Российской Федерации: от наблюдательного исследования к оценке эффективности терапии в клинической практике//Клиническая онкогематология. Фундаментальные исследования и клиническая практика. - 2017. - Т. 10. - N. 3.

4. Hoffmann V.S. et al. Treatment and outcome of 2 904 CML patients from the EUTOS population based registry//Leukemia. Macmillan Publishers Limited, part of Springer Nature., 2016.

5. Baccarani M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013//Blood. 2013. Vol. 122, N 6. P. 872 - 884.

6. Fabarius A. et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV//Blood. - 2011. - Т. 118. - N. 26. - С. 6760 - 6768.

7. Sokal J. E. et al. Prognostic discrimination in" good-risk" chronic granulocytic leukemia//Blood. - 1984. - Т. 63. - N. 4. - С. 789 - 799.

8. Hasford J. et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score//Blood. 2011. Vol. 118, N 3. P. 686 - 692.

9. Marin D., Ibrahim A.R., Goldman J.M. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation//Journal of clinical oncology. - 2011. - Т. 29. - N. 29. - С. 3944 - 3945.

10. Pfirrmann M. et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia//Leukemia. 2016. Vol. 30, N 1. P. 48 - 56.

11. Туркина А.Г. et al. Клинические рекомендации по диагностике и лечению хронического миелолейкоза//Клиническая онкогематология. 2017. Vol. 10, N 3. P. 294 - 316.

12. Dewald G.W. et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia.//Blood. 1998. Vol. 91, N 9. P. 3357 - 3365.

13. Lima L. et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond//Cancer. 2011. Vol. 117, N 6. P. 1245 - 1252.

14. Kantarjian H.M. et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.//Clin. Cancer Res. 2003. Vol. 9, N 1. P. 160 - 166.

15. Hughes T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results//Blood. 2006. Vol. 108, N 1. P. 28 - 37.

16. Branford S., Hughes T.P., Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics//British journal of haematology. - 1999. - Т. 107. - N. 3. - С. 587 - 599

17. Wang L. et al. Serial monitoring of BCR-ABL by peripheral blood real time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia//British journal of haematology. - 2002. - Т. 118. - N. 3. - С. 771 - 777.

18. Hoffmann V.S. et al. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia//Journal of cancer research and clinical oncology. - 2017. - Т. 143. - N. 7. - С. 1311 - 1318.

19. Hochhaus A. et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia//N. Engl. J. Med. 2017. Vol. 376, N 10. P. 917 - 927.

20. Talpaz M. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.//Blood. 2002. Vol. 99, N 6. P. 1928 - 1937.

21. Kantarjian H.M. et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.//Blood. 2002. Vol. 99, N 10. P. 3547 - 3553.

22. Sawyers C.L. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.//Blood. 2002. Vol. 99, N 10. P. 3530 - 3539.

23. Palandri F. et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up//Haematologica. 2009. Vol. 94, N 2. P. 205 - 212.

24. Kantarjian H.M. et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia//Blood. 2003. Vol. 101, N 2. P. 473 - 475.

25. Marin D. et al. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses//Blood. 2003. Vol. 102, N 7. P. 2702 - 2703.

26. Shah N.P. et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034//Am. J. Hematol. 2016. Vol. 91, N 9. P. 869 - 874.

27. Cortes J.E. et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib//Am. J. Hematol. 2016. Vol. 91, N 12. P. 1206 - 1214.

28. Jabbour E. et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy//Blood. 2009. Vol. 113, N 10. P. 2154 - 2160.

29. Kantarjian H.M. et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase//Cancer. 2009. Vol. 115, N 3. P. 551 - 560.

30. Giles F.J. et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study//Leukemia. 2013. Vol. 27, N 1. P. 107 - 112.

31. Hochhaus A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial//Leukemia. 2016. Vol. 30, N 5. P. 1044 - 1054.

32. Cortes J, Saglio G., Kantarjian H., Baccarani M. et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial//J. Clin. Oncol. 2016. Vol. 34, N 20. P. 2333 - 2341.

33. Kantarjian H. et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up//Blood. 2009. Vol. 113, N 25. P. 6322 - 6329.

34. Cortes J. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis//Blood. - 2007. - Т. 109. - N. 8. - С. 3207 - 3213.

35. Saglio G. et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study//Cancer. 2010. Vol. 116, N 16. P. 3852 - 3861.

36. Gambacorti-Passerini C. et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors//Am. J. Hematol. 2015. Vol. 90, N 9. P. 755 - 768.

37. O'Brien S.G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003. Vol. 348, N 11. P. 994 - 1004.

38. Porkka K. et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion//Cancer. 2010. Vol. 116, N 2. P. 377 - 386.

39. Orlandi E.M. et al. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia//Leuk. Res. 2012. Vol. 36, N 1. P. e4 - e6.

40. Giles F.J. et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis//Leukemia. 2013. Vol. 27, N 6. P. 1310 - 1315.

41. Chai-Adisaksopha C., Lam W., Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis//Leukemia & lymphoma. - 2016. - Т. 57. - N. 6. - С. 1300 - 1310.

42. Gambacorti-Passerini C. et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up/Am. J. Hematol. 2014. Vol. 89, N 7. P. 732 - 742.

43. Steegmann J.L. et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia//Leukemia. 2016. Vol. 30, N 8. P. 1648 - 1671.

44. Montani D. et al. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib//Circulation. 2012. Vol. 125, N 17. P. 2128 - 2137.

45. Quintas-Cardama A. et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia//Blood. 2009. Vol. 114, N 2. P. 261 - 263.

46. Cortes J.E. et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial//J. Clin. Oncol. 2018. Vol. 36, N 3. P. 231 - 237.

47. Haouala A. et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib//Blood. 2011. Vol. 117, N 8. P. e75 - e87.

48. Ursan I. D. et al. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: A meta-analysis of clinical trials of tyrosine kinase inhibitors//Journal of managed care & specialty pharmacy. - 2015. - Т. 21. - N. 2. - С. 114 - 122.

49. Branford S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis//Blood. 2003. Vol. 102, N 1. P. 276 - 283.

50. Soverini S. et al. ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia//J. Clin. Oncol. 2005. Vol. 23, N 18. P. 4100 - 4109.

51. Nicolini F.E. et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi (phi)-LMC GROUP).//Leukemia. 2006. Vol. 20, N 6. P. 1061 - 1066.

52. Soverini S. et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia//Clin. Cancer Res. 2006. Vol. 12, N 24. P. 7374 - 7379.

53. Khorashad J.S. et al. Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression//J. Clin. Oncol. 2008. Vol. 26, N 29. P. 4806 - 4813.

54. Nicolini F.E. et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.//Haematologica. 2007. Vol. 92, N 9. P. 1238 - 1241.

55. Jabbour E. et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy//Blood. 2008. Vol. 112, N 1. P. 53 - 55.

56. Velev N. et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I//Cancer. 2010. Vol. 116, N 15. P. 3631 - 3637.

57. Jabbour E. et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations//Blood. 2011. Vol. 117, N 13. P. 3641 - 3647.

58. Nicolini F.E. et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias//Blood. 2011. Vol. 118, N 20. P. 5697 - 5700.

59. Cortes J.E. et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial//Blood. 2018. Vol. 132, N 4. P. 393 - 404.

60. Nickel R.S., Daves M., Keller F. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib//Pediatr. Blood Cancer. 2015. Vol. 62, N 11. P. 2050 - 2051.

61. Branford S. et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia//Leukemia. 2006. Vol. 20, N 11. P. 1925 - 1930.

62. A. et al. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase//Curr. Med. Res. Opin. 2014. Vol. 30, N 7. P. 1345 - 1352.

63. Kantarjian H., Cortes J. Considerations in the Management of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy//J. Clin. Oncol. 2011. Vol. 29, N 12. P. 1512 - 1516.

64. Yeung D.T. et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets//Blood. 2015. Vol. 125, N 6. P. 915 - 923.

65. Cortes J.E. et al. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial//Lancet Haematol. 2016. Vol. 3, N 12. P. e581 - e591.

66. Cervantes F. et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group//Haematologica. 2010. Vol. 95, N 8. P. 1317 - 1324.

67. Baccarani M. et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Annals of oncology. - 2012. - Т. 23. - N. suppl_7. - С. vii72 - vii77.

68. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 1.2013. Available at: www.nccn.org/professionals/physician_gls/PDF/cml.pdf.

69. Lipton J.H. et al. Comparative efficacy among 3rd line post-imatinib chronic phase-chronic myeloid leukemia (CP-CML) patients after failure of dasatinib or nilotinib tyrosine kinase inhibitors. - 2014.

70. Nair A.P. et al. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors//Biol. Blood Marrow Transplant. 2015. Vol. 21, N 8. P. 1437 - 1444.

71. Oehler V.G. et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia//Blood. 2007. Vol. 109, N 4. P. 1782 - 1789.

72. Jabbour E. et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia//Cancer. 2007. Vol. 110, N 2. P. 340 - 344.

73. Shimoni A. et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia//Leukemia. 2009. Vol. 23, N 1. P. 190 - 194.

74. Breccia M. et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib//Leuk. Res. 2010. Vol. 34, N 2. P. 143 - 147.

75. Pavlu J. et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase//Blood. 2010. Vol. 115, N 20. P. 4018 - 4020.

76. Saussele S. et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV//Blood. 2010. Vol. 115, N 10. P. 1880 - 1885.

77. Lee S.-E. et al. Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors//Hematology. 2014. Vol. 19, N 2. P. 63 - 72.

78. Gratwohl A. et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.//Lancet (London, England). 1998. Vol. 352, N 9134. P. 1087 - 1092.

79. Oki Y. et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia//Cancer. 2007. Vol. 109, N 5. P. 899 - 906.

80. A. et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase//Leuk. Lymphoma. 2007. Vol. 48, N 2. P. 283 - 289.

81. Fruehauf S. et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis//Cancer. 2007. Vol. 109, N 8. P. 1543 - 1549.

82. Deau B. et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)//Leuk. Res. 2011. Vol. 35, N 6. P. 777 - 782.

83. Benjamini O. et al. Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia//Am. J. Hematol. 2014. Vol. 89, N 3. P. 282 - 287.

84. Burchert A. et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia//Leukemia. - 2015. - Т. 29. - N. 6. - С. 1331.

85. NCI CTC AE ver 5 [Electronic resource]//November 27, 2017. 2017. P. 155. URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.

86. Quintas-Cardama A. et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia//Cancer. 2004. Vol. 100, N 12. P. 2592 - 2597.

87. Jellinger P.S. et al. American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease//Endocr. Pract. 2017. Vol. 23, N 2.

88. Бойцов С.А. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации//Российский кардиологический журнал. - 2018. - N. 23 (6).

89. Lee N.-R. et al. Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection//Korean J. Intern. Med. Korean Association of Internal Medicine, 2015. Vol. 30, N 4. P. 550.

90. Rajda J., Phatak P.D. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy//Am. J. Hematol. 2005. Vol. 79, N 1. P. 80 - 81.

91. Go S.W. et al. Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.//Tuberc. Respir. Dis. (Seoul). The Korean Academy of Tuberculosis and Respiratory Diseases, 2013. Vol. 75, N 6. P. 256 - 259.

92. Aichberger K.J. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML//Am. J. Hematol. 2011. Vol. 86, N 7. P. 533 - 539.

93. Mealing S. et al. The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis//Experimental hematology & oncology. - 2013. - Т. 2. - N. 1. - С. 5.

94. Soverini S. et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors//Blood. 2009. Vol. 114, N 10. P. 2168 - 2171.